Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NVCR 
Novocure Ltd (NVCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: NVCR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $26.94
1 Year Target Price $26.94
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.05% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.51B USD | Price to earnings Ratio - | 1Y Target Price 26.94 |
Price to earnings Ratio - | 1Y Target Price 26.94 | ||
Volume (30-day avg) 7 | Beta 0.75 | 52 Weeks Range 10.87 - 34.13 | Updated Date 10/13/2025 |
52 Weeks Range 10.87 - 34.13 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.13% | Operating Margin (TTM) -24.89% |
Management Effectiveness
Return on Assets (TTM) -8.64% | Return on Equity (TTM) -48.07% |
Valuation
Trailing PE - | Forward PE 909.09 | Enterprise Value 1359507024 | Price to Sales(TTM) 2.39 |
Enterprise Value 1359507024 | Price to Sales(TTM) 2.39 | ||
Enterprise Value to Revenue 2.16 | Enterprise Value to EBITDA -6.92 | Shares Outstanding 111799290 | Shares Floating 94063451 |
Shares Outstanding 111799290 | Shares Floating 94063451 | ||
Percent Insiders 9.88 | Percent Institutions 85.56 |
Upturn AI SWOT
Novocure Ltd
Company Overview
History and Background
Novocure Ltd. was founded in 2000. The company pioneered Tumor Treating Fields (TTFields) therapy for cancer treatment. It has focused on research, development, and commercialization of TTFields therapy across multiple cancer types.
Core Business Areas
- Oncology: Focuses on developing and commercializing TTFields therapy for solid tumor cancers.
Leadership and Structure
Novocure is led by its executive management team. The company operates with a global structure, including research and development facilities, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Optune (Glioblastoma): Optune is Novocure's primary product, a non-invasive device that delivers TTFields to treat glioblastoma (GBM). Competitors in GBM treatment include chemotherapy (Temozolomide), radiation therapy, and surgery.
- TTFields Therapy for Other Cancers: Novocure is expanding TTFields therapy into other cancers, including non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer and brain metastases. Key competitors are various chemotherapy regimens, targeted therapies, and immunotherapies.
Market Dynamics
Industry Overview
The oncology market is large and competitive. Demand for innovative cancer treatments drives growth, particularly those that improve survival rates and quality of life.
Positioning
Novocure is a leader in TTFields therapy. Its competitive advantage lies in its proprietary technology and clinical data supporting the efficacy of TTFields in specific cancer types.
Total Addressable Market (TAM)
The global oncology market size is substantial, estimated to be hundreds of billions of dollars. Novocure's position relative to this TAM depends on its ability to expand TTFields therapy to additional cancer indications and gain market share.
Upturn SWOT Analysis
Strengths
- Proprietary TTFields technology
- Clinical data supporting efficacy in GBM
- Established reimbursement pathways for Optune
- Expanding into new cancer indications
Weaknesses
- Limited number of approved indications
- High cost of TTFields therapy
- Complex treatment regimen requiring patient compliance
- Reliance on a single technology platform
Opportunities
- Expanding TTFields into additional cancer types
- Developing next-generation TTFields devices
- Partnering with pharmaceutical companies
- Geographic expansion into new markets
Threats
- Competition from established cancer therapies
- Changes in reimbursement policies
- Clinical trial failures in new indications
- Emergence of new cancer treatment technologies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Novocure's advantage is its unique TTFields technology. Its disadvantages include the high cost and complexity of the treatment compared to established therapies.
Growth Trajectory and Initiatives
Historical Growth: Historically, Novocure's growth has been driven by the adoption of Optune in GBM treatment.
Future Projections: Future growth depends on the success of clinical trials in new cancer indications and expansion into new markets.
Recent Initiatives: Recent initiatives include clinical trials in NSCLC, ovarian cancer, pancreatic cancer and brain metastases, and partnerships with pharmaceutical companies.
Summary
Novocure is a pioneer in TTFields therapy, with a promising technology for treating solid tumor cancers, although it is costly and may be inconvenient. Its success hinges on expanding to additional cancer types and continuing to generate positive clinical results. The company must be able to adapt and remain competitive. Threats include competition from established therapies and the uncertainty of clinical trial outcomes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates may not be precise and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novocure Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-10-02 | CEO & Director Ms. Ashley Cordova | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1488 | Website https://www.novocure.com |
Full time employees 1488 | Website https://www.novocure.com | ||
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.